<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647244</url>
  </required_header>
  <id_info>
    <org_study_id>SKS-HIV-002</org_study_id>
    <secondary_id>EudraCT2007-004372-39</secondary_id>
    <nct_id>NCT00647244</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients</brief_title>
  <acronym>SWAP</acronym>
  <official_title>Efficacy and Safety of Switching From AZT to Tenofovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of switching from Retrovir to Tenofovir or Abacavir in
      HIV-infected patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function measured by Cystatin-C and creatinine clearance</measure>
    <time_frame>Weeks 0, 4, 8, 12, 24, 24, 48, 96</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of renal tubule function markers in blood and urine</measure>
    <time_frame>Weeks 0, 12, 24, 48, 96</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone mass assessed by DEXA</measure>
    <time_frame>Weeks 0, 24, 48, 96</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of bone turnover markers in blood and urine</measure>
    <time_frame>Weeks 0, 12, 24, 48, 96</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Weeks 0, 12, 24, 48, 96</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in body composition assessed by patient questionnaire and standardized examination by physician</measure>
    <time_frame>Weeks 0, 12, 24, 48, 96</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in subcutaneous adipose tissue assessed by DEXA</measure>
    <time_frame>Week 0, 24, 48, 96</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with viral load &lt; 40 copies/ml</measure>
    <time_frame>Weeks 0, 4, 8, 12, 24, 48, 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD-4 cell count</measure>
    <time_frame>Weeks 0, 4, 8, 12, 24, 48, 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting triglycerides, HDL and LDL</measure>
    <time_frame>Weeks 0, 12, 24, 48, 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of resistance mutations</measure>
    <time_frame>Weeks 0, 12, 24, 48, 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of adverse events and serious adverse events</measure>
    <time_frame>Weeks 0, 4, 8, 12, 24, 48, 96</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abacavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>Tenofovir disoproxil 245 mg oral tablet once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir</intervention_name>
    <description>Abacavir 300 mg oral tablet twice daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infection with undetectable viral load

          -  Antiretroviral treatment including Retrovir for more than three months

          -  If fertile female: Negative pregnancy test and use of safe contraception

          -  Negative HBs-antigen titer

        Exclusion Criteria:

          -  Prior treatment with abacavir or tenofovir

          -  Resistance towards abacavir or tenofovir

          -  Tissue type HLA-B5701

          -  Renal disease

          -  Diabetes Mellitus

          -  Osteoporosis

          -  Pregnant or lactating subjects

          -  Intravenous drug abuse

          -  Hypersensitivity towards drugs or active ingredient used

          -  ALAT &gt; 5 times upper normal level

          -  Current alcohol or substance abuse judged by the Investigator to potentially interfere
             with subject compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Ã…rhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>December 17, 2010</last_update_submitted>
  <last_update_submitted_qc>December 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alex Lund Laursen, MD, PhD, DmSC</name_title>
    <organization>Department of Infectious Diseases, Aarhus University Hospital, Denmark</organization>
  </responsible_party>
  <keyword>Tenofovir</keyword>
  <keyword>Abacavir</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>HIV</keyword>
  <keyword>Nucleoside analogue reverse transcriptase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

